18 and older, any sex, with Non-small Cell Lung Cancer or Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response Rate (ORR)Primary· At 6 weeks
* ORR: percentage of participants with a complete or partial response
* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Clinical Benefit Rate (CBR)Secondary· At 6 weeks
* CBR is defined as the percentage of patients who have achieved responses (complete or partial) or stable disease.
* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
* Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on st
Group
Value
95% CI
Ramucirumab + Atezolizumab
16
Toxicity and Tolerability as Measured by Number of Participants Who Experienced Adverse EventsSecondary· Through 30 days after completion of treatment (estimated to be 4 months)
-Measured by NCI-CTCAE version 5.0.
Grade 1-2 anemia
Group
Value
95% CI
Ramucirumab + Atezolizumab
8
Grade 3-5 atrial fibrillation
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Grade 3-5 pericardial effusion
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Grade 1-2 ear pain
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Grade 1-2 hypothyroidism
Group
Value
95% CI
Ramucirumab + Atezolizumab
4
Grade 1-2 eye pain
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Grade 1-2 abdominal pain
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Grade 3-5 ascites
Group
Value
95% CI
Ramucirumab + Atezolizumab
1
Overall Survival (OS)Secondary· Through 2 years after completion of treatment (median length of follow-up 16.3 months, full range=2.3-45.6 months)
Group
Value
95% CI
Ramucirumab + Atezolizumab
16.3
7.1 – 20.9
Progression-free Survival (PFS)Secondary· Through 2 years after completion of treatment (median length of follow-up 16.3 months, full range=2.3-45.6 months)
-PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Group
Value
95% CI
Ramucirumab + Atezolizumab
1.0
1.0 – 2.3
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from start of treatment through 30 days after the last administration of the study treatment. All-cause mortality was collected from start of treatment until completion of follow-up. The median length of treatment was 92 days (full range 49 days-812 days). The median length of follow-up was 16.3 months (full range 2.3 months-45.6 months)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients previously treated with ICB.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06996782 — A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
· Phase 1, PHASE2
· recruiting
NCT06675136 — Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal
· Phase 1
· recruiting
NCT07098338 — A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
· Phase 2
· recruiting
NCT06616584 — Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
· Phase 2, PHASE3
· recruiting
NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
· Phase 1, PHASE2
· active not recruiting
Other recruiting trials for Non-small Cell Lung Cancer
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
· Phase 2, PHASE3
· active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit
· Phase 3
· recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
· Phase 3
· recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
· recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
· Phase 2
· not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
· Phase 2
· not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
· Phase 1
· not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
· not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03689855.